**Supplementary Online Content**

**Suppl. Fig. 1.** Subgroup analysis to assess the risk of mild psoriasis in patients with IBD by age and sex.

**Suppl. Fig. 2.** Subgroup analysis to assess the risk of moderate to severe psoriasis in patients with IBD by age and sex.

**Suppl. table 1.** Subgroup analysis to assess the risk of psoriatic arthritis in patients with IBD by age and sex

**Suppl. table 2.** Subgroup analysis to assess the risk of psoriasis in TNF inhibitor-naïve patients with IBD by age and sex

**Suppl. Fig. 1.** Subgroup analysis to assess the risk of mild psoriasis in patients with IBD by age and sex.



CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease; UC, ulcerative colitis.

**Suppl. Fig. 2.** Subgroup analysis to assess the risk of moderate to severe psoriasis in patients with IBD by age and sex.



CD, Crohn’s disease; CI, confidence interval; HR, hazard ratio; IBD, inflammatory bowel disease; UC, ulcerative colitis.

**Suppl. table 1.** Subgroup analysis to assess the risk of psoriatic arthritis in patients with IBD by age and sex

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Incident rate (per 106 person-years) of psoriatic arthritis | Absolutedifference | Adjusted HR (95% CI) | *p* value |
| **IBD** | **control** |
| IBD |  |  |  |  |  |
| Age |  |  |  |  |  |
|  <30 years | 2.15 | 0.53 | 1.62 | 4.06 (0.25–64.96) | 0.3215 |
|  30–49 years | 10.38 | 4.16 | 6.22 | 2.50 (1.04–6.02) | 0.0417 |
|  ≥50 years | 47.76 | 13.08 | 34.67 | 3.65 (2.31–5.76) | <0.0001 |
| Sex  |  |  |  |  |  |
|  Male | 10.64 | 4.58 | 6.06 | 2.32 (1.14–4.72) | 0.0199 |
|  Female | 38.05 | 9.37 | 28.68 | 4.06 (2.49–6.63) | <0.0001 |
| UC |  |  |  |  |  |
| Age |  |  |  |  |  |
|  <30 years | 4.24 | 1.04 | 3.20 | 4.07 (0.25–64.99) | 0.3213 |
|  30–49 years | 11.94 | 5.04 | 6.89 | 2.37 (0.93–6.01) | 0.0701 |
|  ≥50 years | 47.80 | 13.38 | 34.42 | 3.57 (2.17–5.88) | <0.0001 |
| Sex |  |  |  |  |  |
|  Male | 11.50 | 5.66 | 5.84 | 2.03 (0.91–4.52) | 0.0828 |
|  Female | 43.34 | 10.67 | 32.67 | 4.06 (2.41–6.86) | <0.0001 |
| CD |  |  |  |  |  |
| Age |  |  |  |  |  |
|  <30 years | 0.00 | 0.00 | 0.00 | 1 | n.a. |
|  30–49 years | 5.43 | 1.34 | 4.09 | 4.06 (0.25–64.91) | 0.3218 |
|  ≥50 years | 47.55 | 11.65 | 35.90 | 4.08 (1.32–12.65) | 0.0149 |
| Sex |  |  |  |  |  |
|  Male | 8.68 | 2.13 | 6.55 | 4.07 (0.82–20.17) | 0.0856 |
|  Female | 20.53 | 5.06 | 15.47 | 4.06 (1.01–16.22) | 0.0477 |

**Suppl. table 2** Subgroup analysis to assess the risk of psoriasis in TNF inhibitor-naïve patients with IBD by age and sex

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Incident rate (per 106 person-years) of psoriasis | Absolutedifference | Adjusted HR (95% CI) | *p* value |
| **IBD** | **control** |
| IBD |  |  |  |  |  |
| Age |  |  |  |  |  |
|  <30 years | 216.59 | 65.17 | 151.42 | 3.32 (2.45–4.51) | <0.0001 |
|  30–49 years | 207.72 | 71.58 | 136.14 | 2.90 (2.34–3.59) | <0.0001 |
|  ≥50 years | 233.12 | 85.81 | 147.31 | 2.72 (2.23–3.31) | <0.0001 |
| Sex  |  |  |  |  |  |
|  Male | 232.43 | 85.69 | 146.74 | 2.71 (2.29–3.21) | <0.0001 |
|  Female | 203.72 | 63.93 | 139.79 | 3.18 (2.58–3.92) | <0.0001 |
| UC |  |  |  |  |  |
| Age |  |  |  |  |  |
|  <30 years | 230.77 | 54.79 | 175.98 | 4.21 (2.81–6.31) | <0.0001 |
|  30–49 years | 208.25 | 75.7 | 132.55 | 2.75 (2.17–3.49) | <0.0001 |
|  ≥50 years | 224.98 | 83.28 | 141.7 | 2.70 (2.17–3.36) | <0.0001 |
| Sex |  |  |  |  |  |
|  Male | 230.93 | 85.05 | 145.88 | 2.71 (2.23–3.30) | <0.0001 |
|  Female | 204.96 | 64.82 | 140.14 | 3.16 (2.50–3.99) | <0.0001 |
| CD |  |  |  |  |  |
| Age |  |  |  |  |  |
|  <30 years | 195.27 | 80.81 | 114.46 | 2.42 (1.50–3.90) | 0.0003 |
|  30–49 years | 205.72 | 56.11 | 149.61 | 3.66 (2.24–6.01) | <0.0001 |
|  ≥50 years | 272.9 | 98.16 | 174.74 | 2.78 (1.78–4.33) | <0.0001 |
| Sex |  |  |  |  |  |
|  Male | 236.83 | 87.57 | 149.26 | 2.71 (1.95–3.76) | <0.0001 |
|  Female | 198.85 | 60.41 | 138.44 | 3.29 (2.05–5.29) | <0.0001 |